Testosterone: Hormone of power, sex and laughter. Does its progressive loss really represent a risk?

Facebooktwitterlinkedinmail

With the passing of time, all men experience natural changes. Among these the progressive loss of the male hormone known as testosterone (T), has been studied in depth, a loss that brings about the presence of symptoms such as sleep disturbance, changes in mood (mainly irritability), loss of strength, decreased libido and erection quality, among others.

In 1950 an important means of treatment appears for men with low testosterone levels, called hypogonadal. This treatment consists mainly in providing synthetic hormone in different forms such as injections, local applications and spray.

Today you can easily walk the fine line between the normal changes of aging and disease. This has led to a better understanding of the conditions of men with hypogonadism, from which has come the interpretation that there is a direct relationship between low levels of the hormone in the blood and the incidence of increased cardiovascular risk (myocardial infarction), high cholesterol and diabetes, among other ailments.

Recently it has been debated whether the replacement of male hormone promotes the improvement of the condition of hypogonadism or if, on the contrary – and as mentioned in two recent studies in the journals PLOS ONE and JAMA, describing an experiment with a group of men over 65 with a history of acute myocardial infarction undergoing hormone replacement therapy with testosterone – they have a higher risk of cardiovascular events and increased mortality.

To this the scientific community has replied. Some have expressed support, while many others have voiced their opposition to the deleterious effects resulting from the use of hormone replacement therapy.

Meanwhile, the regulator of medicines in the United States, the Food and Drug Administration (FDA for its acronym in English), has spoken and has demanded new and more conclusive scientific studies by companies selling this drug, in order to reassess its safety.

In recent conferences held worldwide in the urological world, the American Congress of Urology (AUA) and the European Congress of Urology (EAU), have spoken about the ongoing debate and have declared their support for the appropriate use, and the timely monitoring of hormone replacement in hypogonadal patients.

Aging is not synonymous with disease nor with the need to stop living with a sense of power, active sexuality and overall well being…